Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
Clinical trial NCT07506057 · RECRUITING
Trial details
- NCT number
- NCT07506057
- Sponsor
- Xiujuan Qu
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-15
- Primary completion
- 2027-07-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.